Will Pfizer Shareholders Get Viatris Stock

It is expected that in the coming months, shareholders of Mylan will vote on the proposed combination of Mylan and Upjohn. More information regarding Viatris, including the company’s full executive management team, board of directors, stock symbol, and logo will be available at a later date.

Will pfizer shareholders get viatris stock. Per the transaction agreement, Pfizer shareholders will receive about 0.12 shares of Viatris for each share of PFE stock. Based on Mylan’s recent closing price of $20.65, this implies a. It is expected that in the coming months, shareholders of Mylan will vote on the proposed combination of Mylan and Upjohn. More information regarding Viatris, including the company’s full executive management team, board of directors, stock symbol, and logo will be available at a later date. Pfizer’s transfer agent, Computershare Trust Company, N.A. ("Computershare") administers our direct stock purchase and dividend reinvestment plan for Pfizer common stock. To learn more, please contact Computershare at: +1-800-PFE-9393 (+1-800-733-9393) (U.S. and Canada) +1-781-575-4591. (Outside U.S. and Canada) Shares of Pfizer rose Thursday, up 6.7%, keeping pace with the S&P 500, which was up 6.2%. Shares of Mylan rose 4.1%. Analysts shrugged off the delay, saying it wouldn’t matter in the long term.

New York-based Pfizer will retain 57% of the new business, while Mylan shareholders will get 43%, according to a statement at the time. The deal is due to close this year. After shareholder and regulatory approval, Mylan and Upjohn will become Viatris, a Latin derivative that represents the new company's "path to three" core goals: "expanding access to medicines. Pfizer shareholders will get new shares representing the balance. Mylan shares initially jumped 20% on the news but quickly lost half that gain by July 30, opening at $20.66, offering a market cap. Pfizer’s legacy-drug business Upjohn will merge with the generic-drug company Mylan to create a new company called Viatris this year. Don’t look now, but here comes Viatris.

Pfizer shareholders will receive shares in Viatris, the new entity created by the merger of Upjohn and Mylan. Viatris should generate annual revenue of between $19 billion and $20 billion with. The planned combination of Pfizer's (PFE +0.2%) Upjohn unit and Mylan N.V. (MYL +2.8%) will be named Viatris, the companies announce.Shareholders will vote on the tie-up, communicated in July, in. HERTFORDSHIRE, England, PITTSBURGH and NEW YORK, Nov. 12, 2019 /PRNewswire/ -- Mylan N.V. (MYL) and Pfizer Inc. (PFE) today announced that the name of the new company to be formed by the planned. Under the deal, Mylan shareholders get 1 share of the new company for each of their shares, and 43% of the resulting stock. Pfizer shareholders will get new shares representing the balance.Mylan.

In addition, Pfizer announced that it plans to spin off and combine Upjohn, its off-patent branded and generic established medicines business, with Mylan N.V. (MYL), creating a new global pharmaceutical company named Viatris. Structured as an all-stock Reverse Morris Trust transaction, Pfizer shareholders will own 57% of the combined new company. Mylan is set to merge with Pfizer’s (PFE) generic-drug unit, called Upjohn, later this year to become a new generic-drug company called Viatris. The merger marks a major turning point for Pfizer. Pfizer shareholders will receive a stock dividend of 0.12 shares per common share owned provided that the equity distribution is structured as a spinout. Pfizer shareholders will receive shares in Viatris, the new entity created by the merger of Upjohn and Mylan. Viatris should generate annual revenue of between $19 billion and $20 billion with.

Pfizer shareholders would own 57% of the combined new company, and Mylan shareholders would own 43%. The Boards of Directors of both Mylan and Pfizer have unanimously approved the transaction. Pfizer plans to sell two assets to its Mylan-Upjohn spinoff Viatris, adding $598 million in yearly revenues, but that's not doing much to raise profitability expectations, analysts warned. Problem. It is expected that in the coming months, shareholders of Mylan will vote on the proposed combination of Mylan and Upjohn. More information regarding Viatris, including the company’s full executive management team, board of directors, stock symbol, and logo will be available at a later date. These documents (when they are available) can also be obtained free of charge from Mylan, upon written request to Mylan, at (724) 514-1813 or investor.relations@mylan.com or from Pfizer on Pfizer.

Pfizer shareholders will own 57% of Viatris and receive a significant dividend from the new company. Once the deal completes, Viatris is expected to generate free cash flow at a rate of $4 billion.